Equity Futures and ETFs Decline Pre-Bell Amid New Tariff Concerns

Equity futures and exchange-traded funds are lower pre-bell Monday amid fresh tariff warnings. Tesla's net sales are primarily from automotive vehicle sales (74.2%), services (10.8%), and energy generation and storage systems (10.3%). The company has 8 manufacturing sites in the US, China, and Germany, with net sales distributed across the US (48.9%), China (21.4%), and other regions (29.7%).

Equity futures and exchange-traded funds are lower pre-bell Monday amid fresh tariff warnings from President Trump. The latest announcement includes a 50% tariff on copper imports and a threat of up to 200% tariffs on pharmaceutical imports if pharma/biotech companies do not move their operations to the United States [1]. The market reaction has been relatively calm, unlike the panic that ensued in April 2025 when similar threats were made.

The pharma/biotech sector has been largely unaffected by the new tariff threat. Companies like Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), Novartis (NVS), Roche (RHHBY), and Merck have already announced significant investments in domestic manufacturing. For instance, Eli Lilly plans to invest over $50 billion in the U.S. since 2020, while Johnson & Johnson has committed more than $55 billion over the next four years [1]. These announcements suggest that the market perceives these tariff threats as opportunities for negotiation rather than immediate panic.

Meanwhile, Tesla, Inc. (TSLA) has seen mixed analyst sentiment. Several hedge funds have increased their stakes in the company, including TFR Capital LLC, which raised its holdings by 41.2% in the first quarter [2]. However, analyst ratings are mixed, with a consensus rating of "Hold" and a target price of $300.19 [2]. The stock has a market capitalization of $1.01 trillion, a P/E ratio of 172.26, and a debt-to-equity ratio of 0.07 [2]. Despite mixed sentiment, Tesla's net sales are primarily from automotive vehicle sales (74.2%), services (10.8%), and energy generation and storage systems (10.3%) [2].

Tesla operates eight manufacturing sites in the U.S., China, and Germany, with net sales distributed across the U.S. (48.9%), China (21.4%), and other regions (29.7%) [2]. The company reported $0.27 earnings per share for the last quarter, missing the consensus estimate of $0.53 [2]. Insider buying and selling have also been notable, with directors and senior vice presidents selling a significant number of shares [2].

References:
[1] https://finance.yahoo.com/news/pharma-companies-remain-calm-amid-133400553.html
[2] https://www.marketbeat.com/instant-alerts/filing-tfr-capital-llc-purchases-2335-shares-of-tesla-inc-nasdaqtsla-2025-07-13/